Spine expert joins biologics company's board of directors: 3 details

Written by Mackenzie Garrity | January 03, 2019 | Print  |

Carmell Therapeutics, a developer of plasma-based bioactive materials to accelerate bone and soft tissue healing, welcomed Wendy DiCicco to its board of directors.

Here are three details:

1. Previously, Ms. DiCicco served as COO and CFO of Centinel Spine.

2. Ms. DiCicco also spent time serving as the president and COO at Camber Spine Technologies. She served as the CFO of various medical device and biotechnology companies.

3. She served on three corporate boards for public and private companies governance, including within the medical device and biotechnology sectors.

“Carmell Therapeutics has developed a unique, innovative technology platform that addresses unmet needs in bone and soft tissue healing,” said Ms. DiCicco. “By applying [internet protocol]-protected science and following a rigorous regulatory pathway, Carmell’s technology shows promise in multiple, high-value indications that improve patients’ quality of life and reduce healthcare costs. I'm delighted to be joining Carmell’s board as they get closer to entering the marketplace.”

More articles on biologics:
U of Arizona cashes $2M grant to study bone regrowth technology: 5 insights
Medscape: Dr. Bert Mandelbaum on biologics for knee osteoarthritis
The biggest challenge in orthopedics is also its best opportunity: key thoughts from Dr. Michael Gerhardt

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months